Navigation Links
NIH announces new program to develop therapeutics for rare and neglected diseases
Date:5/20/2009

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases Program, or TRND.

The program, funded by Congress this spring, is unusual because TRND creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists working on these illnesses. The NIH Office of Rare Diseases Research will oversee the program, and TRND's laboratory operations will be administered by the National Human Genome Research Institute (NHGRI), which also operates the NIH Chemical Genomics Center, a principal collaborator in TRND. Other NIH components will also participate in the initiative.

A rare disease is one that affects fewer than 200,000 Americans. NIH estimates that more than 6,800 rare diseases afflict more than 25 million Americans. However, effective pharmacologic treatments exist for only about 200 of these illnesses. Many neglected diseases also lack treatments. Unlike rare diseases, however, neglected diseases may be quite common in some parts of the world, especially in developing countries where people cannot afford expensive treatments. Private companies seldom pursue new therapies for these types of illness because of high costs and failure rates and the low likelihood of recovering investments or making a profit.

"NIH is gratified that Congress supports finding solutions for millions of our fellow citizens faced with rare or neglected illnesses," said NIH Acting Director Raynard S. Kington, M.D., Ph.D. "The federal government may be the only institution that can take the financial risks needed to jumpstart the development of treatments for these diseases, and NIH clearly has the scientific capability to do the work. We are eager to begin."

Developing Drug
'/>"/>

Contact: Geoffrey Spencer
spencerg@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... lifeplants and animalsto thrive in the oceans, there ... In certain coastal areas, extreme oxygen-starvation produces "dead ... web structure. As dissolved oxygen levels decline, energy ... microbial community metabolism resulting in impacts on the ... the past 50 years, oxygen minimum zones (OMZs) ...
(Date:9/15/2014)... that affect hearing and cognitive function may play roles ... and perceive rhythm, pitch, timbre, tone durations, and formal ... BioEssays article explain that extremes in musical aptitude ... the majority of individuals having moderate aptitude. , "This ... to several underlying genes, and it is influenced to ...
(Date:9/15/2014)... hippopotamuses are demonstrably shown swimming or floating at the ... can,t swim, how did they reach and colonize islands? ... methods, patterns, and timing of the colonization and dispersal ... need to be reconsidered. , "Although land bridge connections ... currently supported by positive geological evidence, neither is ...
Breaking Biology News(10 mins):Decoding virus-host interactions in the oxygen-starved ocean 2Decoding virus-host interactions in the oxygen-starved ocean 3Decoding virus-host interactions in the oxygen-starved ocean 4Decoding virus-host interactions in the oxygen-starved ocean 5
... The octopus arm is extremely flexible. Thanks to ... virtually infinite number of "degrees of freedom"--the octopus ... movements that is unmatched by the human arm. ... differences between the octopus and vertebrates, the octopus ...
... Environmental and genetic factors lead to neural tube defects in 1 ... spontaneous abortion. One cause of these defects is the failure of ... the developing neural tube. , A study in ... the molecular mechanism that directs cells to migrate to the correct ...
... in food-producing animals may be linked with lower levels ... an article in the May 15 issue of Clinical ... is a leading bacterial cause of foodborne illness in ... for physicians to treat, and can result in longer ...
Cached Biology News:How the octopus forms an elbow 2Less antibiotic use in food animals leads to less drug resistance in people, study shows 2
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/14/2014)... Cells regulate protein functions in a wide variety of ... instant, a protein can take on another form and ... proteins that fold wrongly can cause serious diseases such ... proteins also have a tendency to "infect" other molecules ... amyloid fibrils or plaques. These amyloids can damage cells ...
(Date:9/12/2014)... Advancing the front lines of research ... biological threats is the mission of an international ... and the Georgian National Academy of Sciences, and ... Security Programme of the North Atlantic Treaty Organization ... series, the event is titled “Nanotechnology to Aid ...
(Date:9/11/2014)... 2014 RURO, Inc., a leading ... solutions and sample management solutions provider, announces the ... work on the most recent version of its ... already seen mass adoption, especially from multi-license environment ... 5.0 brought an entirely new User Interface and ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3Measuring modified protein structures 2Measuring modified protein structures 3Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Limfinity® Version 5.1 Available 2
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in,Development for Complicated ... Pneumonia (CAP), WASHINGTON, Oct. 27, 2008 ... detailed analysis of CANVAS I, a,globally conducted, multi-center, ... Conference on Antimicrobial Agents and Chemotherapy /,Infectious Diseases ...
... November 2, 2008 at this year,s liver ... - November 4, SAN FRANCISCO, Oct. 27 ... is no approved,medical therapy for this chronic progressive liver ... state-of-the-art lifestyle,intervention program. To do so, 31 overweight or ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
Biology Products: